Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.

ABSTRACT: Radionuclide therapies are an important tool for the management of patients with neuroendocrine neoplasms (NENs). Especially [¹³¹I]MIBG and [¹⁷⁷Lu]Lu-DOTA-TATE are routinely used for the treatment of a subset of NENs, including pheochromocytomas, paragangliomas and gastroenteropancreatic tumors. Some patients suffering from other forms of NENs, such as medullary thyroid carcinoma or neuroblastoma, were shown to respond to radionuclide therapy; however, no general recommendations exist. Although [¹³¹I]MIBG and [¹⁷⁷Lu]Lu-DOTA-TATE can delay disease progression and improve quality of life, complete remissions are achieved rarely. Hence, better individually tailored combination regimes are required. This review summarizes currently applied radionucli

SUBMITTER: Richter S 

PROVIDER: S-EPMC10750207 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature